Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy…

Vera Therapeutics won FDA accelerated approval for TRUTAKNA (atacicept-vymj), the first BAFF/APRIL inhibitor for IgA nephropathy, based on 46% proteinuria reduction in Phase 3 trials. The company is launching with 82 nephrology-focused sales reps and a $425,000 annual list price, targeting 6,000 nephrologists serving ~160,000 US patients. If you sell into nephrology or rare kidney disease, Vera just opened a 6,000-doctor market that was untreated until today — and they've already hired the 82 reps and set the payer conversations. Your window to partner or sell into their launch is the next 90 days, before ORIGIN 3 confirmatory data locks the market position.